CA2107340A1 - Monoclonal antibodies against human tnf-binding protein i (tnf-bp i) - Google Patents

Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)

Info

Publication number
CA2107340A1
CA2107340A1 CA002107340A CA2107340A CA2107340A1 CA 2107340 A1 CA2107340 A1 CA 2107340A1 CA 002107340 A CA002107340 A CA 002107340A CA 2107340 A CA2107340 A CA 2107340A CA 2107340 A1 CA2107340 A1 CA 2107340A1
Authority
CA
Canada
Prior art keywords
tnf
tbp
monoclonal antibodies
binding protein
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002107340A
Other languages
French (fr)
Other versions
CA2107340C (en
Inventor
Gunther Adolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4120213A external-priority patent/DE4120213C2/en
Priority claimed from DE4200049A external-priority patent/DE4200049A1/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2107340A1 publication Critical patent/CA2107340A1/en
Application granted granted Critical
Publication of CA2107340C publication Critical patent/CA2107340C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

-the invention concerns monoclonal antibodies,designated tbp-1, tbp-2 and tbp-6, against the extracellular part of the hu-man 60 k1) TN tumour necrosis [actor receptor (TNF-BP1). These antibodies are suitable for use in highly semsitive immuno-as says for demonstrating the presence of TNF1-BP 1 in body fluids, including urine, and in cell-culture residues. The determination of the TNF-BP1 concentration as the basis for a diagnosis of pathological conditions associated with activation of the TNF re-ceptor system is thus particularly useful if the ~TNF concentration in the organism falls more rapidly than the TNF-BPI con-centration. In addition, tbp-1 and tbp-6 can he used to strengthen the protective action of TNF-BP1 against (~-TNF and/or (.beta.-TNF-
CA002107340A 1991-06-19 1992-06-13 Monoclonal antibodies against human tnf-binding protein i (tnf-bp i) Expired - Lifetime CA2107340C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4120213A DE4120213C2 (en) 1991-06-19 1991-06-19 Monoclonal antibodies against TNF-binding protein I (TNF-BP I)
DEP4120213.9 1991-06-19
DEP4200049.1 1992-01-03
DE4200049A DE4200049A1 (en) 1992-01-03 1992-01-03 New monoclonal antibodies specific for tumour necrosis factor binding protein
PCT/EP1992/001335 WO1992022666A1 (en) 1991-06-19 1992-06-13 Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)

Publications (2)

Publication Number Publication Date
CA2107340A1 true CA2107340A1 (en) 1992-12-20
CA2107340C CA2107340C (en) 2003-06-10

Family

ID=25904672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002107340A Expired - Lifetime CA2107340C (en) 1991-06-19 1992-06-13 Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)

Country Status (6)

Country Link
EP (1) EP0589982B1 (en)
AT (1) ATE198770T1 (en)
AU (1) AU668351B2 (en)
CA (1) CA2107340C (en)
DE (1) DE59209888D1 (en)
WO (1) WO1992022666A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270943B (en) * 1993-05-14 1997-05-26 Mini Ricerca Scient Tecnolog TYPE I TNF ALFA ANTI-RECEPTOR ANTI-RECEPTOR ANTI-PRODUCTION PROCEDURES AND THEIR USES
EP0846169B1 (en) * 1995-08-04 2003-03-19 Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.D. MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-ALPHA RECEPTORS p55 and p75 AS WELL AS AGAINST TNF-ALPHA AND ITS ANALOGUES
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
EP1089859B1 (en) 1999-03-30 2003-07-02 Geo S.r.l. Method for cutting blocks of stone and frame cutting machine for carrying out said method
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
EP0393438B1 (en) * 1989-04-21 2005-02-16 Amgen Inc. TNF-receptor, TNF-binding protein and DNA coding therefor
DE4006269A1 (en) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antibody which binds to tumour necrosis factor receptors
US5224919A (en) * 1990-09-07 1993-07-06 Graphic Packaging Corporation Method and apparatus for attaching insert panels to carton blanks
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION

Also Published As

Publication number Publication date
AU668351B2 (en) 1996-05-02
DE59209888D1 (en) 2001-02-22
ATE198770T1 (en) 2001-02-15
EP0589982A1 (en) 1994-04-06
CA2107340C (en) 2003-06-10
EP0589982B1 (en) 2001-01-17
WO1992022666A1 (en) 1992-12-23
AU1974592A (en) 1993-01-12

Similar Documents

Publication Publication Date Title
NZ241048A (en) Monoclonal antibody to tissue necrosis factor #a#, pharmaceutical compositions and hybridoma
CA2133106A1 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
HK1001462A1 (en) Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells
EP0334165A3 (en) Monoclonal antibodies
DE69433378D1 (en) HUMANE B LYMPHOBLASTOID CELL LINE WHICH ANTI-GANGLIOSIDE ANTIBODIES SECRETED
DE69333076D1 (en) TESTING AND TREATING DEMYELINATING DISEASES LIKE MULTIPLE Sclerosis
CA2107340A1 (en) Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)
SE8701905D0 (en) A METHOD AND A KIT FOR THE DIAGNOSIS OF IGA NEPHROPATHY
AU6864894A (en) Method to detect bone and other connective tissue disorders in humans and animals
EP0948536A4 (en) A g protein-coupled receptor with an enlarged extracellular domain
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
WO2005003299A3 (en) Polynucleotides encoding novel guanylate binding proteins (gbp's)
ATE70311T1 (en) MONOCLONAL ANTIBODIES AGAINST HUMAN ISER RECEPTORS ON LYMPHOCYTES, HYBRIDOMAS PRODUCING THESE ANTIBODIES, AND RESPONSE APPROACHES TO THE USE OF THESE ANTIBODIES.
Lederer et al. Characterization and identification of interleukin-1 receptors on bovine fibroblasts
Adolf Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
Feng Study on the expression and function of Thy-1.
RU94039686A (en) Method of assay of cellular immunity activity
Zupan Truncated forms of the human nerve growth factor receptor
ZA876738B (en) Polypeptide related compounds,compositions and test kits useful for the alleviation,treatment and diagnosis of autoimmune diseases
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis
MX9800191A (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry